Insurers Say Mallinckrodt Sales Strategy Cost Them $320M
A pair of insurers seeking antitrust damages from drugmaker Mallinckrodt over the sales of its Acthar gel put their expert witnesses before a Delaware bankruptcy judge on Friday, claiming they overpaid...To view the full article, register now.
Already a subscriber? Click here to view full article